| Literature DB >> 30877508 |
Anelise Samara Nazari Formagio1,2, Pedro Cruz de Oliveira Junior3, Carla Roberta Ferreira Volobuff4, Candida Aparecida Leite Kassuya4, Diego Cegobia Ferreira5, Claudia Andrea Lima Cardoso5, Maria Helena Sarragiotto6, Zefa Valdevina Pereira3.
Abstract
Palicourea crocea (Sw.) Roem. and Schult., "douradinha," are used by treat inflammation (edema). Croceaine A (PC-1) was isolated from P. crocea (MEPC) leaves and studied for its antioxidant and anti-inflammatory activity, as well as concentrations of constituents and acute toxicity. The phenols and polyphenolics compounds and HPLC/DAD were determined. The antioxidant activity were evaluated for DPPH, ABTS, and MDA. MEPC (300, 100, and 300 mg/kg) and PC-1 (10 and 30 mg/kg) were tested for anti-inflammatory effects in paw edema, pleurisy, cold sensitivity, and mechanical hyperalgesia. Acute toxicity is also described. MEPC contained high concentrations of phenolic and flavonoid compounds (≤ 800.35 mg/g), as well as caffeic acid, ferulic acid, rutin, and quercetin, revealed by HPLC-DAD analysis. MEPC displayed antioxidant activity against ABTS radicals (IC50 = 68.5 μg/mL) and MDA (74%). MEPC and alkaloid PC-1 demonstrated an anti-edematogenic effect in Cg-induced paw edema in 2 and 4 h, and also significantly reduced mechanical hyperalgesia, cold response to acetone in mice, at 3 and 4 h after injection, as well as leukocyte migrationin the pleurisy model. No toxicity was detected by MEPC. For the first time, P. crocea was evaluated for its antioxidant, systemic anti-inflammatory, and anti-hyperalgesic activities.Entities:
Keywords: anti-hyperalgesic; antioxidant; croceaine A; douradina; edema; pleurisy
Year: 2019 PMID: 30877508 DOI: 10.1007/s10753-019-00966-7
Source DB: PubMed Journal: Inflammation ISSN: 0360-3997 Impact factor: 4.092